The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker ...

The respiratory syncytial virus (RSV) vaccine (Abrysvo) was linked with fewer hospitalizations and emergency department (ED) ...

Recent findings from a multi-state study reveal that the RSV vaccine is approximately 80% effective in preventing severe ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will expand the number of people eligible for ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

Respiratory syncytial virus, or RSV, typically presents as mild, with symptoms similar to the common cold for adults and ...